Aptinyx Announces Proposed Public Offering of Common Stock
October 20 2020 - 04:01PM
Business Wire
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical
company developing transformative therapies for the treatment of
brain and nervous system disorders, today announced that it intends
to offer and sell 12,000,000 shares of its common stock in an
underwritten public offering. All of the shares sold in the
offering will be sold by Aptinyx. Aptinyx also expects to grant the
underwriters a 30-day option to purchase up to an additional
1,800,000 shares to be issued and sold in the public offering. The
offering is subject to market and other conditions, and there can
be no assurances as to whether or when the offering may be
completed, or as to the actual size and terms of the offering.
SVB Leerink, Piper Sandler and Cantor are acting as joint
bookrunning managers for the offering.
Aptinyx intends to use the net proceeds received from the
offering to advance the development of its novel NMDA receptor
modulators, including NYX-2925, NYX-783, and NYX-458, in
development for chronic pain, PTSD, and cognitive impairment,
respectively, and for working capital and other general corporate
purposes.
The shares of common stock in the public offering will be issued
by Aptinyx pursuant to a shelf registration statement that was
previously filed with, and declared effective by, the Securities
and Exchange Commission (the “SEC”). The offering will be made only
by means of the written prospectus and prospectus supplement that
form a part of the registration statement. A preliminary prospectus
supplement and the accompanying prospectus relating to the public
offering will be filed by the Company with the SEC. Copies of the
preliminary prospectus supplement and the accompanying prospectus
may be obtained, when available, on the SEC's website at
http://www.sec.gov or by contacting SVB Leerink LLC, Attention:
Syndicate Department, One Federal St., 37th Floor, Boston, MA,
02110, by telephone at (800) 808-7525, ext. 6132, or by email at
syndicate@svbleerink.com; or Piper Sandler & Co., Attn:
Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN,
55402, by telephone at (800) 747-3924, or by email at
prospectus@psc.com; or Cantor Fitzgerald & Co., Attention:
Capital Markets, 499 Park Ave., 6th Floor, New York, NY, 10022, or
by email at prospectus@cantor.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any offer or sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or jurisdiction.
About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company
focused on the discovery, development, and commercialization of
proprietary synthetic small molecules for the treatment of brain
and nervous system disorders.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the potential public offering. Risks that contribute to the
uncertain nature of the forward-looking statements include: the
success, cost, and timing of the company’s product candidate
development activities and planned clinical studies; the company’s
ability to execute on its strategy; regulatory developments in the
United States and foreign countries; as well as those risks and
uncertainties set forth in the company’s most recent annual report
on Form 10-K and in its other filings and reports with the United
States Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Aptinyx undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were
made.
Source: Aptinyx Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201020006197/en/
Investor Contact: Nick Smith Aptinyx Inc. ir@aptinyx.com
847-871-0377
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Mar 2023 to Mar 2024